

# Victoria Atkinson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11470333/publications.pdf>

Version: 2024-02-01

90  
papers

16,413  
citations

201385

27  
h-index

64668

79  
g-index

91  
all docs

91  
docs citations

91  
times ranked

16123  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	1.3	28
2	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19.	0.3	3
3	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. <i>European Journal of Cancer</i> , 2022, 163, 79-87.	1.3	17
4	Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinoradiological response outcomes. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 536-545.	0.9	5
5	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. <i>Cancers</i> , 2022, 14, 2300.	1.7	6
6	Patient Judgement of Change with Elective Surgery Correlates with Patient Reported Outcomes and Quality of Life. <i>Healthcare (Switzerland)</i> , 2022, 10, 999.	1.0	6
7	In-Depth Characterisation of Real-World Advanced Melanoma Patients Receiving Immunotherapies and/or Targeted Therapies: A Case Series. <i>Cancers</i> , 2022, 14, 2801.	1.7	0
8	Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. <i>Current Oncology Reports</i> , 2022, 24, 1273-1280.	1.8	5
9	Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in <i>BRAF</i> <sup>V600E/K</sup> -mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9516-9516.	0.8	6
10	Utility and timeliness of somatic genetic testing for patients enrolled in the molecular screening and therapeutics (MoST) study at Princess Alexandra Hospital (PAH).. <i>Journal of Clinical Oncology</i> , 2022, 40, e15039-e15039.	0.8	0
11	Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16033-e16033.	0.8	0
12	Implementing PROMS for elective surgery patients: feasibility, response rate, degree of recovery and patient acceptability. <i>Journal of Patient-Reported Outcomes</i> , 2022, 6, .	0.9	10
13	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	2.9	27
14	Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. <i>European Journal of Cancer</i> , 2021, 142, 10-17.	1.3	16
15	Human CD141 <sup>+</sup> dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model. , 2021, 9, e001963.		25
16	Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real-world study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1371-1379.	0.9	0
17	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9500-9500.	0.8	4
18	Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9508-9508.	0.8	41

#	ARTICLE	IF	CITATIONS
19	Analysis of metastatic melanoma treated with immune checkpoint inhibitors and the rates of adverse events of colitis and hepatitis.. Journal of Clinical Oncology, 2021, 39, e21591-e21591.	0.8	1
20	Hospital admissions and subsequent outcomes from immune-related adverse events.. Journal of Clinical Oncology, 2021, 39, e21590-e21590.	0.8	0
21	Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.. Journal of Clinical Oncology, 2021, 39, 9504-9504.	0.8	23
22	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.. Journal of Clinical Oncology, 2021, 39, 9525-9525.	0.8	7
23	5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i>V600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clinical Cancer Research, 2021, 27, 5225-5235.	3.2	82
24	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	1.3	12
25	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. ANZ Journal of Surgery, 2021, 91, 3-13.	0.3	7
26	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. Clinical Cancer Research, 2021, 27, 5280-5288.	3.2	21
27	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 2021, 153, 168-178.	1.3	14
28	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
29	Protocol for implementation of the "AusPROM"™ recommendations for elective surgery patients: a mixed-methods cohort study. BMJ Open, 2021, 11, e049937.	0.8	5
30	First-In-Human Phase I Study of a Next-Generation, Oral, TGFÎ² Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clinical Cancer Research, 2021, 27, 6666-6676.	3.2	27
31	Non-â€sclerosing large duct cholangitis secondary to checkpoint inhibition. Internal Medicine Journal, 2021, 51, 1758-1759.	0.5	0
32	383-â€Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695. , 2021, 9, A417-A417.		2
33	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer, 2021, 158, 156-168.	1.3	19
34	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. JAMA Oncology, 2020, 6, 519.	3.4	287
35	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research, 2020, 30, 261-267.	0.6	27
36	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. Journal of Clinical Oncology, 2020, 38, 3937-3946.	0.8	119

#	ARTICLE	IF	CITATIONS
37	Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. <i>Scientific Reports</i> , 2020, 10, 17687.	1.6	14
38	The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. <i>European Journal of Cancer</i> , 2020, 138, 68-76.	1.3	10
39	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020, 26, 1557-1563.	15.2	78
40	Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. , 2020, 8, e001681.		57
41	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	13.9	256
42	Adjuvant nivolumab versus ipilimumab in resected stage IIIBâ€C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477.	5.1	330
43	Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. <i>BMC Nephrology</i> , 2020, 21, 391.	0.8	20
44	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020, 26, 5086-5091.	3.2	27
45	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 358-372.	5.1	94
46	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma. , 2020, 8, e001806.		110
47	Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10000-10000.	0.8	21
48	Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III <i>BRAF</i> V600â€ mutant melanoma: Five-year analysis of COMBI-AD.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10001-10001.	0.8	20
49	Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10016-10016.	0.8	6
50	The antiâ€PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced <i>BRAF</i> V600â€ mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10028-10028.	0.8	8
51	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 941-946.	15.2	256
52	Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 936-940.	15.2	246
53	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	5.1	50
54	Reply to E. HindiÃ© and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019, 37, 1356-1358.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Effectiveness of dabrafenib in the treatment of patients with BRAF V600 mutant metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	0.6	6
56	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295
57	Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9514-9514.	0.8	3
58	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600 mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9531-9531.	0.8	31
59	Phase 1b study of PV-10 and anti-PD-1 in advanced cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9559-9559.	0.8	12
60	A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9600-TPS9600.	0.8	16
61	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	13.9	1,441
62	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation positive melanoma. <i>British Journal of Cancer</i> , 2018, 118, 777-784.	2.9	19
63	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 672-681.	5.1	732
64	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600 Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	0.8	226
65	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	1.3	97
66	The changing paradigm of management in melanoma brain metastases. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 453-458.	0.7	3
67	Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e367.	5.1	7
68	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9502-9502.	0.8	52
69	Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9545-9545.	0.8	2
70	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9590-9590.	0.8	9
71	Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9591-9591.	0.8	8
72	Preliminary findings from part 1 of COMBI-i: A phase III study of anti-PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 189-189.	0.8	26

#	ARTICLE	IF	CITATIONS
73	Reply to "Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy". British Journal of Cancer, 2017, 116, e15-e15.	2.9	1
74	Recent advances in malignant melanoma. Internal Medicine Journal, 2017, 47, 1114-1121.	0.5	40
75	Adjuvant Dabrafenib plus Trametinib in Stage III <i>BRAF</i> -Mutated Melanoma. New England Journal of Medicine, 2017, 377, 1813-1823.	13.9	1,192
76	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine, 2017, 377, 1824-1835.	13.9	1,752
77	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncology, The, 2017, 18, 1202-1210.	5.1	211
78	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. JAMA Oncology, 2017, 3, 1511.	3.4	131
79	The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma. Melanoma Research, 2017, 27, 168-170.	0.6	23
80	Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1).. Journal of Clinical Oncology, 2017, 35, 9513-9513.	0.8	4
81	KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.. Journal of Clinical Oncology, 2017, 35, 9545-9545.	0.8	10
82	A case of acute paraneoplastic neurological syndrome in BRAF mutant metastatic melanoma. Melanoma Research, 2016, 26, 425-428.	0.6	2
83	Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 5-12.	0.7	22
84	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2016, 17, 1248-1260.	5.1	832
85	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	1.8	12
86	Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation. New England Journal of Medicine, 2015, 372, 320-330.	13.9	4,795
87	Medical management of malignant melanoma. Australian Prescriber, 2015, 38, 74-78.	0.5	24
88	Acute Atrial Stretch Results in Conduction Slowing and Complex Signals at the Pulmonary Vein to Left Atrial Junction. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1189-1197.	2.1	51
89	<i>BRAF</i> <sup>V600E</sup> Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy With or Without Trametinib. JAMA Dermatology, 2014, 150, 1079.	2.0	26
90	Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma. New England Journal of Medicine, 2014, 371, 1867-1876.	13.9	1,824